company background image
003020 logo

Hefei Lifeon Pharmaceutical SZSE:003020 Stock Report

Last Price

CN¥18.28

Market Cap

CN¥3.5b

7D

-2.0%

1Y

-40.7%

Updated

28 Jun, 2024

Data

Company Financials

Hefei Lifeon Pharmaceutical Co., Ltd.

SZSE:003020 Stock Report

Market Cap: CN¥3.5b

003020 Stock Overview

Engages in the research, development, production, and sale of pharmaceutical preparations and active pharmaceutical ingredients.

003020 fundamental analysis
Snowflake Score
Valuation4/6
Future Growth0/6
Past Performance3/6
Financial Health6/6
Dividends2/6

Hefei Lifeon Pharmaceutical Co., Ltd. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Hefei Lifeon Pharmaceutical
Historical stock prices
Current Share PriceCN¥18.28
52 Week HighCN¥32.52
52 Week LowCN¥13.74
Beta0.18
11 Month Change-12.33%
3 Month Change3.08%
1 Year Change-40.73%
33 Year Change-26.56%
5 Year Changen/a
Change since IPO11.29%

Recent News & Updates

Hefei Lifeon Pharmaceutical (SZSE:003020) Has Announced A Dividend Of CN¥0.50

May 23
Hefei Lifeon Pharmaceutical (SZSE:003020) Has Announced A Dividend Of CN¥0.50

Investors Still Aren't Entirely Convinced By Hefei Lifeon Pharmaceutical Co., Ltd.'s (SZSE:003020) Earnings Despite 25% Price Jump

May 22
Investors Still Aren't Entirely Convinced By Hefei Lifeon Pharmaceutical Co., Ltd.'s (SZSE:003020) Earnings Despite 25% Price Jump

Hefei Lifeon Pharmaceutical's (SZSE:003020) Profits May Not Reveal Underlying Issues

Apr 29
Hefei Lifeon Pharmaceutical's (SZSE:003020) Profits May Not Reveal Underlying Issues

Recent updates

Hefei Lifeon Pharmaceutical (SZSE:003020) Has Announced A Dividend Of CN¥0.50

May 23
Hefei Lifeon Pharmaceutical (SZSE:003020) Has Announced A Dividend Of CN¥0.50

Investors Still Aren't Entirely Convinced By Hefei Lifeon Pharmaceutical Co., Ltd.'s (SZSE:003020) Earnings Despite 25% Price Jump

May 22
Investors Still Aren't Entirely Convinced By Hefei Lifeon Pharmaceutical Co., Ltd.'s (SZSE:003020) Earnings Despite 25% Price Jump

Hefei Lifeon Pharmaceutical's (SZSE:003020) Profits May Not Reveal Underlying Issues

Apr 29
Hefei Lifeon Pharmaceutical's (SZSE:003020) Profits May Not Reveal Underlying Issues

Shareholder Returns

003020CN PharmaceuticalsCN Market
7D-2.0%-2.6%-2.7%
1Y-40.7%-15.9%-17.4%

Return vs Industry: 003020 underperformed the CN Pharmaceuticals industry which returned -15.9% over the past year.

Return vs Market: 003020 underperformed the CN Market which returned -17.4% over the past year.

Price Volatility

Is 003020's price volatile compared to industry and market?
003020 volatility
003020 Average Weekly Movement6.8%
Pharmaceuticals Industry Average Movement5.6%
Market Average Movement6.7%
10% most volatile stocks in CN Market10.1%
10% least volatile stocks in CN Market4.2%

Stable Share Price: 003020 has not had significant price volatility in the past 3 months.

Volatility Over Time: 003020's weekly volatility (7%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
20021,315Xiaojuan Dengwww.lifeonapi.com

Hefei Lifeon Pharmaceutical Co., Ltd. engages in the research, development, production, and sale of pharmaceutical preparations and active pharmaceutical ingredients. It operates through Pharmaceutical Industry, Pharmaceutical Wholesale and Distribution, and Pharmaceutical Retail Business segments. The company offers active pharmaceutical ingredients, which include nifedipine, paliperidone, prilocaine, methylphenidate hydrochloride, dimercaptosuccinic acid, doxazosin mesylate, paeonol, urea, felodipine, and troxerutin; and medical preparations, such as osmotic pump preparations, central nervous systems, Chinese patent medicines, eye drops, external use, and general oral medicines.

Hefei Lifeon Pharmaceutical Co., Ltd. Fundamentals Summary

How do Hefei Lifeon Pharmaceutical's earnings and revenue compare to its market cap?
003020 fundamental statistics
Market capCN¥3.50b
Earnings (TTM)CN¥190.90m
Revenue (TTM)CN¥1.42b

18.3x

P/E Ratio

2.5x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
003020 income statement (TTM)
RevenueCN¥1.42b
Cost of RevenueCN¥520.31m
Gross ProfitCN¥902.28m
Other ExpensesCN¥711.37m
EarningsCN¥190.90m

Last Reported Earnings

Mar 31, 2024

Next Earnings Date

Aug 31, 2024

Earnings per share (EPS)1.00
Gross Margin63.42%
Net Profit Margin13.42%
Debt/Equity Ratio1.6%

How did 003020 perform over the long term?

See historical performance and comparison

Dividends

2.3%

Current Dividend Yield

42%

Payout Ratio
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.